Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Michael T. Andriole, President and CEO of Chimerix Inc . (NASDAQ:CMRX), recently sold 7,370 shares of the company's common stock, according to a recent SEC filing. The shares were sold at a weighted ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...

Equities research analysts at Wedbush boosted their FY2028 earnings per share estimates for shares of Chimerix in a research note issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They ...

Chimerix (CMRX) announced the FDA has accepted its New Drug Application, or NDA, seeking accelerated approval for dordaviprone as a treatment ...

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced ...

Chimerix ...

DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement ...

Investing.com -- Chimerix（纳斯达克股票代码：CMRX）股价上涨12.5%，此前该公司宣布美国食品和药物管理局（FDA）已接受其新药申请（NDA），用于治疗复发性H3 ...